Home About Us Pipeline News Investors Contacts Careers

Puma Biotechnology, Inc. Corporate Fact Sheet


RECENT NEWSEVENTSCLINICAL TRIALS



February 26, 2020 - Puma Biotechnology Receives U.S. FDA Approval of Supplemental New Drug Application for Neratinib to Treat HER2-Positive Metastatic Breast Cancer
Read

February 20, 2020 - Puma Biotechnology Reports Fourth Quarter and Full Year Financial Results
Read

February 5, 2020 - Puma Biotechnology to Host Conference Call to Discuss Fourth Quarter and Full Year 2019 Financial Results
Read

January 13, 2020 - Puma Biotechnology Releases Slides to be Presented at the J.P. Morgan Healthcare Conference
Read

January 7, 2020 - Puma Biotechnology to Present at the J.P. Morgan Healthcare Conference
Read

December 13, 2019 - Puma Biotechnology Presents Interim Results of Phase II CONTROL Trial of Neratinib in Extended Adjuvant Treatment of HER2-Positive Early Stage Breast Cancer at the 2019 SABCS
Read

December 12, 2019 - plasmaMATCH Trial Shows Neratinib Activity in ERBB2 (HER2) Mutant Metastatic Breast Cancer
Read

December 11, 2019 - Puma Biotechnology Presents Results from the Phase II SUMMIT Trial of Neratinib for ERBB2 (HER2) Mutant, HER2 Non-Amplified, Metastatic Breast Cancer at the 2019 San Antonio Breast Cancer Symposium
Read

December 2, 2019 - Puma Biotechnology Licensing Partner Specialised Therapeutics Receives Marketing Approval in Singapore for NERLYNX® (neratinib) for Extended Adjuvant Treatment of Early Stage Hormone Receptor Positive HER2-Positive Breast Cancer
Read

December 2, 2019 - Puma Biotechnology Amends License Agreement with Pierre Fabre to Include Additional Countries
Read

November 6, 2019 - Puma Biotechnology Reports Third Quarter 2019 Financial Results
Read

November 5, 2019 - Puma Biotechnology Licensing Partner CANbridge Pharmaceuticals Receives Registration Approval in Hong Kong for NERLYNX® (neratinib) for Extended Adjuvant Treatment of Early Stage Hormone Receptor Positive HER2-Positive Breast Cancer
Read

November 4, 2019 - Puma Biotechnology to Present at the Credit Suisse Healthcare Conference
Read

October 23, 2019 - Puma Biotechnology to Host Conference Call to Discuss Third Quarter Financial Results
Read

October 2, 2019 - FDA Approves Labeling Supplement for Puma Biotechnology’s NERLYNX® (neratinib) for the Extended Adjuvant Treatment of HER2-Positive Early Stage Breast Cancer
Read

September 25, 2019 - Puma Biotechnology to Present at Cantor Global Healthcare Conference
Read

September 11, 2019 - Puma Biotechnology Announces U.S. FDA Acceptance of Supplemental New Drug Application for Neratinib to Treat HER2-Positive Metastatic Breast Cancer
Read

September 4, 2019 - Puma Biotechnology Licensing Partner Pint Pharma Receives Marketing Authorization for NERLYNX® (neratinib) for Extended Adjuvant Treatment of Early Stage Hormone Receptor Positive, HER2-Positive Breast Cancer
Read

September 3, 2019 - FDA Grants Orphan Drug Designation to Puma Biotechnology’s NERLYNX® for the Treatment of Breast Cancer Patients with Brain Metastases
Read

September 3, 2019 - Puma Biotechnology to Present at the H.C. Wainwright 21st Annual Global Investment Conference
Read


Upcoming Events

Feb. 20, 2020 - Puma Biotechnology 4Q-2019 Financial Results Conference Call
More



Past Events

Jan. 15, 2020 - 38th Annual J.P. Morgan Healthcare Conference
More

Dec. 10, 2019 - San Antonio Breast Cancer Symposium
More

Nov. 12, 2019 - Credit Suisse 28th Annual Healthcare Conference
More

Nov. 6, 2019 - Puma Biotechnology 3Q-2019 Financial Results Conference Call
More

October 3, 2019 - Cantor Global Healthcare Conference
More

September 10, 2019 - H.C. Wainwright 21st Annual Global Investment Conference
More

September 5, 2019 - Citi’s 14th Annual Biotech Conference
More

August 8, 2019 - Puma Biotechnology 2Q-2019 Financial Results Conference Call
More

Puma-Sponsored Trials
Investigator-Sponsored Trials




Annual Report

2018 Annual Report

 Annual Report Archives

Contact

Puma Biotechnology, Inc.
10880 Wilshire Blvd., Suite 2150
Los Angeles, CA 90024
424-248-6500 Main
424-248-6501 Fax

Medical Inquiries:
1-844-MED-PUMA (1-844-633-7862), or
medinfo@pumabiotechnology.com

Business Development:
info@pumabiotechnology.com

Investor Relations:
ir@pumabiotechnology.com